A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas

Soragni, Alice, Janzen, Deanna M., Johnson, Lisa M., Lindgren, Anne G., Thai-Quynh Nguyen, Anh, Tiourin, Ekaterina, Soriaga, Angela B., Lu, Jing +5 more·2016·Cancer Cell
DOI 10.1016/j.ccell.2015.12.002

Cited by (343)

Items 301–343 of 343

  1. An Insight into Cancer from Biomolecular Condensates
    Quratulain Maqsood, Aleena Sumrin, Muhammad Saleem, Rukhsana Perveen, Nazim Hussain, Muhammada Mahnoor, Muhammad Akhtar, Abdul Wajid, Esha Ameen · 2023 · Cancer Screening and Prevention
  2. BRCA2, PALB2, RECQL4 Germline Pathogenic Variants, and Somatic TP53 Mutation in Triple Metachronous Malignancies: A Case Report and Literature Review
    Yang Liu, Hui Yang, Xueshu Fu, Luting Zhong, Ping Xu, Fang Fang, Ying Liu, Qing Li, Yanan Yan, Shanchuang Wei et al. · 2024 · International Medical Case Reports Journal
  3. p53 TAD2 Domain (38–61) Forms Amyloid-like Aggregates in Isolation
    Kundlik Gadhave, Shivani Krishna Kapuganti, Pushpendra Mani Mishra, Rajanish Giri · 2022 · ACS Chemical Neuroscience
  4. A peptide strategy for inhibiting different protein aggregation pathways in disease
    Tommaso Garfagnini, Luca Ferrari, Margreet B. Koopman, Sem Halters, Eline C van Kappel, Guy Mayer, Madelon M. Maurice, Stefan Rüdiger, Assaf Friedler · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  5. Unraveling the Complex Pathology of Neurodegenerative Diseases: Multiple Prions, Cross-β Networks and Baicalein's ReproFold
    Hsiang‐Yu Chang, I‐Fan Wang · 2024 · Preprints.org
  6. Characterization and functional analysis of mutant p53 secretome in human cancer
    Reshma Shakya · 2016 · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
  7. Biomolecular hydration in protein-protein interaction, protein stability and aggregation and lead optimization : computational studies
    Mohan Rajan Pradhan · 2017
  8. The effect of chemotherapy treatment on Ribosomal RNA integrity and ribosomal protein composition in ovarian cancer cells
    Kyle Mispel-Beyer · 2017 · Lu Zone Ul (Laurentian University)
  9. D EMOGRAPHIC CHARACTERISTICS OF BASAL CEL L CARCINOMA: A RETROSPECTIVE STUDY OF 1884 LESIONS
    Goran Stevanović, Irena Janković, Jadranka Paravina, Dimitrije Janković, Milena Veličković · 2017 · Acta Medica Medianae
  10. Gain-of-function and dominant-negative effects of distinct p53 mutations in lung tumours
    Frances K. Turrell · 2018 · Apollo (University of Cambridge)
  11. In Vivo Discoveries in MDM2-Mediated p53 Regulation
    Nicole R. Tackmann · 2019 · Carolina Digital Repository (University of North Carolina at Chapel Hill)
  12. Novel Strategies in High-Risk AML
    John Sutton Welch · 2019 · Clinical Lymphoma Myeloma & Leukemia
  13. Increasing Chemosensitivity in Colorectal Cancer
    Lauren Alicia Agro · 2019 · TSpace (University of Toronto)
  14. Promising agents on the horizon
    Alice Soragni, Meghna S. Trivedi · 2020 · Elsevier eBooks
  15. Identification and Characterization of TPRKB Dependency in TP53 Deficient Cancers
    Kelly Kennaley · 2019 · Deep Blue (University of Michigan)
  16. Knockdown CD44 Promotes Amyloid-Beta Degradation in Ovarian Cancer Cells By Regulating CD36 Expression
    Ying Xu, Yunge Gao, Luomeng Qian, Wangyou Feng, Tingting Song, Yuanfeng Li, Fenfen Guo, Jiao Zheng, Yu Li, Jianfang Zhang et al. · 2021 · Research Square
  17. DESARROLLO DE APLICACIÓN UBICUA SENSIBLE AL CONTEXTO PARA SISTEMAS ANDROID
    Vicente Vázquez Mor · 2011
  18. An Insight into Targeted Therapy for Ovarian Cancer
    Abhishek Chatterjee, Vineet Kumar Mishra, Susmita Saha, Snehasikta Swarnakar · 2022 · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects
  19. HSP90-stabilized proteins as therapeutic targets in cancer
    Luisa Klemke · 2021
  20. Targeting MDM2, the antagonist of the tumor suppressor p53
    Anusha Sriraman · 2018
  21. Faculty Opinions recommendation of Atomic structures of TDP-43 LCD segments and insights into reversible or pathogenic aggregation.
    Martin Vabulas · 2018 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  22. BRCA2, PALB2, RECQL4 germline mutations, and TP53 somatic mutations in endometrial cancer, with ovarian cancer and unilateral breast cancer: A triple metachronous malignancies case report
    Yang Liu, Xueshu Fu, Luting Zhong, Ping Xu, Fang Fang, Ying Liu, Qing Li, Ya'nan Yan, Shanchuang Wei, Chunhua Zhang · 2022
  23. Acetylation of Smad1 promotes tumorigenesis and chemoresistance via competitive attenuation of p300-mediated p53 acetylation in glioblastoma
    Lingli Gong, Daxing Xu, Zhening Pu, Bo Zhang, Ying Yin, Ji Li, Jingjing Wang, Yaling Hu, Meng Jiao, Rui Zhang et al. · 2022 · Research Square
  24. p53 amyloid pathology with cancer grades and p53 mutations
    Shinjinee Sengupta, Namrata Singh, Ajoy Paul, Debalina Datta, Debdeep Chatterjee, Semanti Mukherjee, Laxmikant G. Gadhe, Jyoti Devi, M Yeshwant, Mohit Kumar Jolly et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  25. Restoration of Tumor Suppression to Cancer Carrying p53 Mutations
    Mohammad Nurul Amin, Yu Liu · 2023 · IntechOpen eBooks
  26. Mutant p53 Induces Amyloid Aggregation in p63 and p73 Liquid Droplets: Mechanistic Insights into Oncogenic Phase Transitions
    Jerson Lima Silva, Elaine C. Petronilho, Guilherme de Andrade, Gileno dos S. de Sousa, Fernando Pereira de Almeida, Michelle F. Mota, Mayra A. Marques, Tuane C. R. G. Vieira, Guilherme A. P. de Oliveira · 2024 · Research Square
  27. Oncogenic Phase Transitions: How Mutant p53 Drives Amyloid Formation in p63 and p73 Liquid Droplets
    Elaine C. Petronilho, Guilherme Caldas de Andrade, Gileno dos S. de Sousa, Fernando Pereira de Almeida, Michelle F. Mota, Mayra A. Marques, Tuane C. R. G. Vieira, Guilherme A. P. de Oliveira, Jerson Lima Silva · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  28. Phage libraries screening on P53: Yield improvement by zinc and a new parasites-integrating analysis
    Sihem Ben Abid, Emna Ketata, Inès Yacoubi, Salma Abdelmoula-Souissi, Lamia Djemal, Aida Koubaa, Raja Mokdad‐Gargouri, Ali Faouzi Gargouri · 2024 · PLoS ONE
  29. Mesoscopic p53-rich clusters represent a new class of protein condensates
    David S. Yang, Alexander Tilson, Michael B. Sherman, Navin Varadarajan, Peter G. Vekilov · 2025 · Biophysics Reviews
  30. Cell Settling, Migration, and Stochastic Cancer Expression Suggest Potassium Flux Per H + - Sensitive KCN Members Associated with Oncogenes and Histone/DNA Modulators Potentially Initiates pH-Reversal
    Marie E. Beckner · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  31. Consensus DNA Inhibits p53 Aggregation but Fails to Rescue Mutants
    Matthew Steinsaltz, Gregory-Neal W Gomes, Zachary A. Levine · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  32. Cell Settling, Migration, and Stochastic Cancer Gene Expression Suggest Potassium Membrane Flux May Initiate pH Reversal
    Marie E. Beckner · 2025 · Biomolecules
  33. p53 Aggregation in cancer: Molecular mechanisms, functional disruptions, and targeted therapies
    Asma Shah, Sara K. Al-Marzooqi, Sameer Mirza, Ammira S. Al-Shabeeb Akil, Mayank Singh, Muzafar Ahmad Macha, Ajaz Ahmad Bhat · 2025 · Advances in protein chemistry and structural biology
  34. Novel Approaches for Detecting TP53 Mutations and Targeted Therapeutic Strategies: Emerging Insights Into Cytoplasmic p53 Aggregates in Ovarian Cancer
    Naoyuki Iwahashi, Kazuhiko Ino · 2025 · Journal of obstetrics and gynaecology research
  35. Développement d'un biosenseur fluorescent d'un mutant de p53 sujet à l'agrégation dans les cancers
    Morgan Pellerano · 2019
  36. Effet de l’inactivation du gène suppresseur de tumeur p53 et de sa réactivation pharmacologique sur la réponse cytotoxique anti-tumorale
    Marie Chollat-Namy · 2020
  37. Microfluidic Technology in Cancer Treatment Current Applications and Future Potentials
    Xinye Cai · 2026 · Highlights in Science Engineering and Technology
  38. Targeting the Undruggable: Deep Learning-Driven Design of Peptide Therapeutics in Cancer
    Ha Thi Ngoc Nguyen, Bao Hong Ngoc Le, Nhung Thi Hong Van, Trinh Thi Tuyet Tran, Tuan Minh Nguyen · 2026 · Pharmaceuticals
  39. Targeting cell cycle arrest for augmented immunotherapy via glutathione-responsive nanoparticles with CDK inhibitors and self-immolative dual drug conjugates
    Lin Zhu, Zheng Cao, Jinjian Liu, Fan Huang, Haihua Xiao, Lijun Yang, Changyuan Yu, Kun Shang · 2026 · Nano Today
  40. Multi-Site Aggregation of p53: Insights from Self- and Co-Aggregation of Multiple Aggregation-Prone Regions
    Jing He, Haoxin Sun, Zheng Gong, Xiaoting Wu, Lujun Hong, Tianjing Guo, Jiangtao Lei · 2026 · ACS Omega
  41. Covalent stabilization of mutant p53 suppresses aggregation and restores apoptotic signaling
    Jerson Lima Silva, Giulia D. S. Ferretti, Ruan Ribeiro, Mariana da Paz, Raissa dos Santos, Francisca Guedes da Silva, Gileno dos S. de Sousa, Michelle F. Mota, Julia Quarti, Danilo Predes et al. · 2026 · Research Square
  42. Cancer–Alzheimer inverse comorbidity from epidemiology to protein self-assembly
    Yanxian Zhang, Lijin Wang, Jialun Wei, Nazmul Shuzan, Jie Zheng · 2026 · Frontiers in Endocrinology
  43. Aggregation of Mutant p53 Alters Sialylated and Sulfated Glycan Profiles and Enhances Siglec-9 Ligand Availability in Ovarian Cancer
    Midori Ikezaki, Noa Mori, Yoshiko Takeda‐Uchimura, Naoyuki Iwahashi, Megumi Fujino, Kaho Nishioka, Kazuhiko Ino, Yoshito Ihara, Masakazu Fujimoto, Yukio Fujiwara et al. · 2026 · Laboratory Investigation